

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**2026 FIRST QUARTERLY REPORT**

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the first quarterly report of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively “**We**” or “**Our**”) for financial year 2026 (the “**2026 First Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards Accounting Standards issued by the International Accounting Standards Board (the “**IFRS Accounting Standards**”) (as applicable) and has not been audited.

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, April 27, 2026

*As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.*

\* For identification purposes only

## **I. Important Notice**

- 1.1 The Board, the Directors, the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2026 First Quarterly Report and that there are no false information, misleading statements or material omissions in the 2026 First Quarterly Report, and shall assume several and joint legal responsibilities.
- 1.2 Ge Li, the person in charge of the Company, Ming Shi, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial information contained in the 2026 First Quarterly Report.
- 1.3 The 2026 First Quarterly Report of the Company has not been audited.
- 1.4 Definitions

### **Definitions of frequently-used terms**

|                  |   |
|------------------|---|
| “A Share(s)”     | domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB   |
| “Board”          | the board of Directors of the Company   |
| “CDMO”           | Contract Development and Manufacturing Organization, a CMO that in addition to comprehensive drug manufacturing services, also provides process development, formulation development, clinical trial medications, production of chemically or biologically synthesized active pharmaceutical ingredients, intermediate manufacturing, formulation production (such as powders and injectables), and packaging, as well as customized research and development services for related products |
| “China” or “PRC” | the People’s Republic of China, which for the purpose of this quarterly report and for geographical reference only, refers to mainland China  |

|                                     |  |
|-------------------------------------|--|
| “CRDMO”                             | Contract Research Development and Manufacturing Organization   |
| “CRO”                               | Contract Research Organization, an academic or commercial scientific institution that provides specialized services to pharmaceutical companies and research institutions during the drug development process through contractual agreements   |
| “Director(s)”                       | the director(s) of the Company or any one of them  |
| “end of the Reporting Period”       | March 31, 2026   |
| “H Share(s)”                        | overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on The Stock Exchange of Hong Kong Limited   |
| “Reporting Period”                  | January 1, 2026 to March 31, 2026  |
| “RMB” or “RMB million” or “billion” | Renminbi yuan or million yuan or billion yuan  |
| “R&D”                               | research and development   |
| “Share(s)”                          | ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares   |
| “Small molecule drug”               | small molecule drugs mainly refer to chemically synthesized drugs, typically with a molecular weight of less than 1,000 daltons, with advantages such as wide application and based on well-established theories, currently, the majority of mature drugs on the market are small molecule drugs |
| “WuXi Chemistry”                    | chemistry business of the Company  |
| “WuXi Testing”                      | testing business of the Company  |
| “WuXi Biology”                      | biology business of the Company  |

“year-over-year” or  
“YoY”

for the Reporting Period as compared to the same period in  
the previous year

## **II. Company Profile**

As a global company with operations across Asia, Europe, and North America, we provide a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, our integrated, end-to-end services include chemistry drug CRDMO, biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products in a cost-effective and efficient way.

We have always adhered to the highest international quality standard. Since our inception, we have won an esteemed reputation in the global drug R&D market, attributed to its exceptional service record and a robust intellectual property protection system. The quality of service established by the Company enjoys significant recognition and credibility within the industry. Through continuous optimization and the exploration of business synergies across various sectors, we enhance our ability to serve customers worldwide and strengthen our unique integrated CRDMO business model, offering a true one-stop service that fulfills clients’ needs from drug discovery, development and manufacturing.

### III. Major financial data

#### 1. Major financial statement items and financial indicators

| Item  | Unit: RMB                             |  |   |
|---|---------------------------------------|--|---|
|   | For the Reporting Period              | For the same period of the previous year | Year-over-year increase/decrease (%)  |
| Revenue   | 12,435,776,568.29                     | 9,654,595,304.28                         | 28.81   |
| Total profit  | 5,607,280,256.21                      | 4,279,893,550.88                         | 31.01   |
| Net profit attributable to the owners of the Company  | 4,651,517,987.76                      | 3,671,960,950.47                         | 26.68   |
| Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items | 4,275,624,429.82                      | 2,329,266,627.00                         | 83.56   |
| Net cash flow from operating activities   | 3,595,810,326.53                      | 3,195,429,861.72                         | 12.53   |
| Basic earnings per share (RMB/share)  | 1.59                                  | 1.29                                     | 23.26   |
| Diluted earnings per share (RMB/share)  | 1.58                                  | 1.28                                     | 23.44   |
| Weighted average return on net assets (%)   | 5.68                                  | 6.08                                     | Decreased by 0.40 percentage points   |
|   |                                       |  | Increase/decrease as at the end of the Reporting Period as compared to the end of the previous year (%) |
|   | As at the end of the Reporting Period | As at the end of the previous year       |   |
| Total assets  | 107,414,481,341.25                    | 103,120,968,579.11                       | 4.16  |
| Equity attributable to the owners of the Company  | 84,221,755,533.76                     | 79,712,290,246.44                        | 5.66  |

## 2. Non-recurring gain or loss items and amounts

Applicable     Not applicable

Unit: RMB

| Non-recurring gain or loss item  | Amount for the Reporting Period | Description  |
|--|---------------------------------|--|
| Gain or loss on disposal of non-current assets, including the write-off portion of asset impairment provisions that have been made   | 9,950,968.91                    |  |
| Government grants from various countries included in profit or loss of the current period, except for those that are closely related to the Company's normal business operations, in compliance with policy regulations, and have a continuous impact on the Company's profit or loss according to established standards | 57,274,083.90                   |  |
| Gain or loss arising from changes in fair value of financial assets and financial liabilities held by a non-financial enterprise, and gain or loss arising from disposal of financial assets and financial liabilities, except effective hedging business related to the Company's normal business operations            | 353,476,519.14                  | It was mainly due to changes in fair value and gains and losses on disposal of non-current financial assets and derivative financial instruments |
| Other non-operating income and expenses other than the above items   | -6,511,053.23                   |  |
| Other gain or loss items that meet the definition of non-recurring gain or loss  | 9,225,403.12                    | It was due to interest income from long-term receivables generated from divestiture of certain business by the Company                           |
| Less: Effect of income tax   | 47,363,251.36                   |  |
| Impact on non-controlling interests (after tax)  | 159,112.54                      |  |
| Total  | <u>375,893,557.94</u>           |  |

Reasons should be provided for identifying items not listed in the “Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Gain or Loss” as non-recurring gain or loss items with significant amounts, as well as for classifying the non-recurring gain or loss items listed in the “Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Gain or Loss” as recurring gain or loss items.

Applicable     Not applicable

### 3. Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

✓ Applicable    □ Not applicable

| Item  | Change (%) | Main reasons   |
|---|------------|--|
| Revenue   | 28.81      | Please refer to the analysis below for details   |
| Total profit  | 31.01      | It was primarily attributable to the Company's continued focus on and strengthening of the CRDMO business model, resulting in sustained revenue growth. Simultaneously, the Company continued to optimize production processes and operational efficiency, and the increased capacity efficiency brought about by the growth of late-stage clinical and commercial projects improved overall profitability |
| Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items | 83.56      |  |

Unit: Ten thousand RMB

| Reportable Segments                         | First quarter of 2026 | First quarter of 2025 | Change(%)    |
|---|-----------------------|-----------------------|--------------|
| WuXi Chemistry                              | 1,061,979.86          | 739,097.03            | 43.69        |
| WuXi Testing                                | 112,729.28            | 88,452.13             | 27.45        |
| WuXi Biology                                | 66,813.14             | 60,707.27             | 10.06        |
| Others                                      | 2,055.38              | 3,603.04              | -42.95       |
| Subtotal of Continuing Operations           | 1,243,577.66          | 891,859.47            | 39.44        |
| Discontinued Operations <sup>(Note 1)</sup> | —                     | 73,600.06             | -100.00      |
| Total                                       | <u>1,243,577.66</u>   | <u>965,459.53</u>     | <u>28.81</u> |

*Note 1:* In accordance with the Accounting Standard for Business Enterprises of PRC, the Group has classified the relevant businesses that have signed equity sale agreements, completed sales, or those being discontinued during the Reporting Period or comparative periods, as discontinued operations. Comparative disclosures have been adjusted accordingly.

*Note 2:* The sum of the data may be inconsistent with the total due to rounding.

In the first quarter of 2026, total revenue reached RMB12.44 billion, up 28.8% YoY. Revenue from continuing operations increased 39.4% YoY. By the end of March 2026, backlog for continuing operations reached RMB59.77 billion, up 23.6% YoY.

*(1) WuXi Chemistry*

Revenue of WuXi Chemistry reached RMB10.62 billion, up 43.7% YoY. During the Reporting Period:

- We are accelerating proactive capacity planning. We plan to initiate the new Changzhou site ahead of schedule to better meet growing customer demand.
- Small molecule drug discovery service (“**R**”) continues to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to global customers. Meanwhile, 83 molecules were converted from R to D phase. Guided by our “follow-the-customer” and “follow-the-molecule” strategies, we have built trusted partnerships that underpin the sustainable growth of our CRDMO business.
- Small molecule development and manufacturing (“**D**” & “**M**”, Development and Manufacturing) service maintains strong momentum.
  - i. The small molecule CDMO pipeline continued to expand, adding 328 new molecules in the first quarter of 2026. As of March 31, 2026, our pipeline reached 3,550 molecules, including 89 commercial projects, 94 in phase III, 386 in phase II and 2,981 in phase I and pre-clinical stages. Notably, commercial and phase III projects increased by 9 during the first quarter.
  - ii. With our business model continuously attracting high-quality molecules, and the pipeline steadily advancing to late stages, aligned with proactive capacity planning and strong execution, revenue of small molecule D&M rose 80.1% YoY to RMB6.93 billion in the first quarter of 2026.
- TIDES business (oligo and peptides) sustains rapid growth.
  - i. TIDES revenue grew 6.1% YoY to RMB2.38 billion in the first quarter of 2026, with full-year TIDES revenue expected to grow about 40% YoY.
  - ii. TIDES D&M customers grew 28% YoY, and molecules grew 59% YoY.

## (2) *WuXi Testing*

Revenue of WuXi Testing reached RMB1.13 billion, up 27.4% YoY. During the Reporting Period:

- Revenue from drug safety evaluation services grew 34.8% YoY, maintaining an industry-leading position in the Asia-Pacific region.
- The Company is committed to actively enabling customers in global licensing deals. New modality business continued its strong momentum, contributing more than 30% of WuXi Testing revenue in the first quarter of 2026, while maintaining its leading position in areas including nucleic acids, conjugates, multispecific antibodies and peptides.
- The Company continued to drive excellence across R&D and service capabilities, with Drug Metabolism and Pharmacokinetics steadily advancing new capacity in Qidong and Shanghai to efficiently respond to growing and diversified customer demand.

## (3) *WuXi Biology*

Revenue of WuXi Biology reached RMB0.67 billion, up 10.1% YoY. During the Reporting Period:

- WuXi Biology builds differentiated drug discovery capabilities in emerging therapeutic areas. It actively expands global business and efficiently generates downstream opportunities for the CRDMO model by continuously contributing more than 20% of the Company's new customers.
- We efficiently enable our global customers through integrated *in vitro* & *in vivo* drug discovery capabilities, cross-regional collaboration and end-to-end solutions in emerging areas.
- We achieved rapid revenue growth driven by accelerated progress in integrated *in vitro* screening and enhanced *in vivo* pharmacology capabilities. Non-oncology business maintained a competitive edge, serving as a key growth contributor.
- New modality business continued to drive growth, contributing more than 30% of WuXi Biology revenue in the first quarter of 2026, supported by rapid new customer expansion in areas including nucleic acids, antibody conjugates and peptides.

## IV. Information about shareholders

### 1. Total number of ordinary shareholders, total number of preference shareholders with voting rights restored and shareholdings of the top 10 shareholders as at the end of the Reporting Period

Unit: Share

|  |         |
|--|---------|
| Total number of ordinary shareholders as at the end of the Reporting Period <sup>(Note 1)</sup>                    | 285,204 |
| Total number of preference shareholders with voting rights restored as at the end of the Reporting Period (if any) | 0       |

### Shareholdings of top 10 Shareholders (excluding shares borrowed from financial institution backed securities)

| Full name of shareholders   | Nature of shareholders | Number of Shares held | Percentage (%) | Number of Shares subject to trading restrictions | Pledged, marked or frozen Shares Status | Number |
|---|------------------------|-----------------------|----------------|--|---|--------|
| HKSCC NOMINEES LIMITED <sup>(Note 2)</sup>  | Overseas legal entity  | 510,434,558           | 17.1071        | 0  | Unknown                                 | 0      |
| Hong Kong Securities Clearing Company Limited <sup>(Note 3)</sup>   | Overseas legal entity  | 173,881,937           | 5.8276         | 0  | Nil                                     | 0      |
| G&C VI Limited  | Overseas legal entity  | 127,309,054           | 4.2667         | 0  | Nil                                     | 0      |
| G&C IV Hong Kong Limited  | Overseas legal entity  | 93,135,472            | 3.1214         | 0  | Nil                                     | 0      |
| Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership)<br>(北京中民銀孚投資管理有限公司 — 嘉興宇祥投資合夥企業(有限合夥))                | Other                  | 77,511,585            | 2.5978         | 0  | Nil                                     | 0      |
| G&C V Limited   | Overseas legal entity  | 65,076,978            | 2.1810         | 0  | Nil                                     | 0      |
| China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Traded Open-end Index Securities Investment Fund<br>(中國建設銀行股份有限公司 — 易方達滬深300醫藥衛生交易型開放式指數證券投資基金) | Other                  | 34,838,905            | 1.1676         | 0  | Nil                                     | 0      |
| G&C VII Limited   | Overseas legal entity  | 33,696,017            | 1.1293         | 0  | Nil                                     | 0      |

**Shareholdings of top 10 Shareholders  
(excluding shares borrowed from financial institution backed securities)**

| Full name of shareholders   | Nature of shareholders | Number of Shares held | Percentage (%) | Number of Shares subject to trading restrictions | Pledged, marked or frozen Shares Status | Number |
|---|------------------------|-----------------------|----------------|--|---|--------|
| Bank of China Co., Ltd. — Huabao CSI Medical Service Exchange Traded Open-end Index Securities Investment Fund<br>(中國銀行股份有限公司 — 華寶中證醫療交易型開放式指數證券投資基金) | Other                  | 31,813,631            | 1.0662         | 0  | Nil                                     | 0      |
| SUMMER BLOOM INVESTMENTS (I) PTE. LTD.  | Overseas legal entity  | 31,721,901            | 1.0632         | 0  | Nil                                     | 0      |

**Shareholdings of top 10 holders of Shares not subject to trading restrictions  
(excluding shares borrowed from financial institution backed securities)**

| Full name of shareholders   | Number of Shares not subject to trading restrictions | Class                           | Number      |
|---|--|---------------------------------|-------------|
| HKSCC NOMINEES LIMITED <sup>(Note 2)</sup>  | 510,434,558  | Overseas-listed foreign shares  | 510,434,558 |
| Hong Kong Securities Clearing Company Limited <sup>(Note 3)</sup>   | 173,881,937  | RMB-denominated ordinary shares | 173,881,937 |
| G&C VI Limited  | 127,309,054  | RMB-denominated ordinary shares | 127,309,054 |
| G&C IV Hong Kong Limited  | 93,135,472   | RMB-denominated ordinary shares | 93,135,472  |
| Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaying Yuxiang Investment Partnership (Limited Partnership)<br>(北京中民銀孚投資管理有限公司 — 嘉興宇祥投資合夥企業(有限合夥))                | 77,511,585   | RMB-denominated ordinary shares | 77,511,585  |
| G&C V Limited   | 65,076,978   | RMB-denominated ordinary shares | 65,076,978  |
| China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Traded Open-end Index Securities Investment Fund<br>(中國建設銀行股份有限公司 — 易方達滬深300醫藥衛生交易型開放式指數證券投資基金) | 34,838,905   | RMB-denominated ordinary shares | 34,838,905  |
| G&C VII Limited   | 33,696,017   | RMB-denominated ordinary shares | 33,696,017  |

**Shareholdings of top 10 holders of Shares not subject to trading restrictions  
(excluding shares borrowed from financial institution backed securities)**

| Full name of shareholders   | Number of Shares<br>not subject to<br>trading restrictions  | Class and number of Shares         |            |
|---|---|------------------------------------|------------|
|   |   | Class                              | Number     |
| Bank of China Co., Ltd. — Huabao CSI Medical Service Exchange Traded Open-end Index Securities Investment Fund (中國銀行股份有限公司 — 華寶中證醫療交易型開放式指數證券投資基金)  | 31,813,631  | RMB-denominated<br>ordinary shares | 31,813,631 |
| SUMMER BLOOM INVESTMENTS (I) PTE. LTD.  | 31,721,901  | RMB-denominated<br>ordinary shares | 31,721,901 |
| Description of connected relationships or concerted actions of the above shareholders   | G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited, G&C VII Limited and Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) being part of the top 10 shareholders of the Company, are acting in concert. |                                    |            |
| The participation of top 10 shareholders and top 10 shareholders holding Shares not subject to trading restrictions in financing, financial notes and financial institution backed securities business (if any) | Not applicable  |                                    |            |

*Note 1:* As of the end of the Reporting Period, the total number of ordinary shareholders was 285,204, among them, there were 285,145 holders of A Shares and 59 registered holders of H Shares.

*Note 2:* HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

*Note 3:* Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB denominated ordinary shares under the Shanghai-Hong Kong Stock Connect.

*Note 4:* In the event of any discrepancy between the English translation and the Chinese version of the full name of shareholder, the Chinese version shall prevail.

**2. Participation of shareholders holding 5% or more of the shares, top 10 shareholders and top 10 holders of shares not subject to trading restrictions in the borrowing of shares from financial institution backed securities**

Applicable     Not applicable

**3. Changes of top 10 shareholders and top 10 holders of shares not subject to trading restrictions as compared with the previous period arising from borrowing/return of shares from financial institution backed securities**

Applicable     Not applicable

## V. Other reminders

Other important information about the Company's operating conditions during the Reporting Period that investors need to be reminded of and pay attention to

Applicable  Not applicable

## VI. Quarterly financial statements

### 1. Type of auditor's opinion

Applicable  Not applicable

### 2. Financial statements

#### Consolidated Balance Sheet

As at March 31, 2026

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

| Item                                   | As at<br>March 31,<br>2026 | As at<br>December 31,<br>2025 |
|--|----------------------------|-------------------------------|
| <b>Current Assets:</b>                 |                            |                               |
| Bank balances and cash                 | 35,905,237,313.79          | 35,131,309,638.47             |
| Financial assets held for trading      | 7,479,221,505.81           | 5,806,211,811.42              |
| Derivative financial assets            | 116,808,345.33             | 68,657,103.15                 |
| Note receivables                       | 6,737,203.77               | 18,672,249.95                 |
| Trade receivables                      | 7,700,936,967.37           | 7,262,654,076.97              |
| Prepayments                            | 317,915,447.87             | 246,628,413.97                |
| Other receivables                      | 346,414,417.16             | 724,565,155.08                |
| Including: Interest receivables        | 101,013,056.90             | 28,476,379.02                 |
| Dividend receivables                   | —                          | —                             |
| Inventories                            | 9,965,880,371.58           | 8,993,244,894.24              |
| Contract assets                        | 528,212,738.24             | 469,517,512.56                |
| Held for sale assets                   | —                          | 26,045,621.53                 |
| Non-current assets due within one year | 1,399,386,889.12           | 1,402,987,153.42              |
| Other current assets                   | 1,402,557,817.74           | 1,526,562,259.73              |
| Total Current Assets                   | 65,169,309,017.78          | 61,677,055,890.49             |

| Item  | As at<br>March 31,<br>2026 | As at<br>December 31,<br>2025 |
|---|----------------------------|-------------------------------|
| <b>Non-current Assets:</b>                  |                            |                               |
| Long-term equity investments                | 2,275,267,437.71           | 2,144,876,912.07              |
| Other non-current financial assets          | 8,464,145,695.00           | 8,131,208,431.70              |
| Fixed assets                                | 19,517,849,361.35          | 19,999,931,768.14             |
| Construction in progress                    | 6,709,257,892.76           | 5,875,518,226.97              |
| Productive biological assets                | 1,024,158,000.00           | 1,013,273,000.00              |
| Right-of-use assets                         | 729,801,197.15             | 763,114,562.83                |
| Intangible assets                           | 1,254,435,323.44           | 1,280,523,344.96              |
| Goodwill                                    | 863,384,053.29             | 864,388,850.17                |
| Long-term deferred expenditures             | 337,909,304.42             | 366,834,780.31                |
| Deferred tax assets                         | 565,719,437.59             | 531,296,901.24                |
| Other non-current assets                    | 503,244,620.76             | 472,945,910.23                |
| Total Non-current Assets                    | 42,245,172,323.47          | 41,443,912,688.62             |
| Total Assets                                | 107,414,481,341.25         | 103,120,968,579.11            |
| <b>Current Liabilities:</b>                 |                            |                               |
| Short-term borrowings                       | 5,977,731,732.75           | 5,986,138,418.73              |
| Derivative financial liabilities            | 90,740,849.75              | —                             |
| Note payables                               | 13,482,000.00              | —                             |
| Trade payables                              | 2,837,890,623.18           | 2,449,523,876.15              |
| Contract liabilities                        | 2,764,250,761.82           | 2,709,159,889.23              |
| Payroll payables                            | 1,267,117,491.99           | 2,326,308,898.74              |
| Tax payables                                | 2,764,818,288.65           | 2,762,813,534.62              |
| Other payables                              | 3,161,353,124.05           | 2,841,705,486.56              |
| Including: Interest payables                | 924,219.45                 | 1,016,663.76                  |
| Dividend payables                           | 23,606,550.00              | 23,606,550.00                 |
| Non-current liabilities due within one year | 164,100,660.51             | 159,618,101.21                |
| Total Current Liabilities                   | 19,041,485,532.70          | 19,235,268,205.24             |
| <b>Non-current Liabilities:</b>             |                            |                               |
| Long-term borrowings                        | 1,818,800,000.00           | 1,819,100,000.00              |
| Lease liabilities                           | 418,299,246.95             | 455,256,654.87                |
| Deferred income                             | 919,451,614.16             | 948,171,287.50                |
| Deferred tax liabilities                    | 444,815,538.54             | 415,458,829.98                |
| Total Non-current Liabilities               | 3,601,366,399.65           | 3,637,986,772.35              |
| Total Liabilities                           | 22,642,851,932.35          | 22,873,254,977.59             |

| <b>Item</b>  | <b>As at<br/>March 31,<br/>2026</b> | <b>As at<br/>December 31,<br/>2025</b> |
|--|-------------------------------------|--|
| <b>Owners' Equity (or Shareholders' Equity):</b>                                 |                                     |  |
| Paid-in capital (or share capital)   | 2,983,757,155.00                    | 2,983,757,155.00                       |
| Capital reserve  | 33,200,448,846.31                   | 33,077,292,637.94                      |
| Less: Treasury shares  | 3,838,766,784.75                    | 3,842,179,016.17                       |
| Other comprehensive income   | -415,727,814.09                     | -147,106,673.86                        |
| Special reserve  | —                                   | —                                      |
| Surplus reserve  | 1,491,878,577.50                    | 1,491,878,577.50                       |
| Undistributed profit   | 50,800,165,553.79                   | 46,148,647,566.03                      |
| Total Equity (or Shareholders' Equity) attributable to the owners of the Company | 84,221,755,533.76                   | 79,712,290,246.44                      |
| Non-controlling interests  | 549,873,875.14                      | 535,423,355.08                         |
| Total Owners' Equity (or Shareholders' Equity)                                   | 84,771,629,408.90                   | 80,247,713,601.52                      |
| Total Liabilities and Owners' Equity (or Shareholders' Equity)                   | 107,414,481,341.25                  | 103,120,968,579.11                     |

|  |          |
|--|----------|
| Person in charge of the Company:       | Ge Li    |
| Chief Financial Officer:               | Ming Shi |
| Director of the Accounting Department: | Jin Sun  |

## Consolidated Income Statement

January to March 2026

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

| Item  | First quarter<br>of 2026 | First quarter<br>of 2025 |
|---|--------------------------|--------------------------|
| I. Total revenue  | 12,435,776,568.29        | 9,654,595,304.28         |
| Including: Revenue  | 12,435,776,568.29        | 9,654,595,304.28         |
| II. Total cost  | 7,433,446,073.33         | 6,712,128,987.72         |
| Including: Cost   | 6,167,822,778.36         | 5,574,529,171.26         |
| Taxes and surcharges  | 92,179,839.85            | 84,736,857.59            |
| Selling expenses  | 182,056,633.56           | 194,051,886.09           |
| Administrative expenses   | 709,748,017.05           | 562,794,264.61           |
| R&D expenses  | 266,956,709.12           | 224,408,414.09           |
| Finance expenses  | 14,682,095.39            | 71,608,394.08            |
| Including: Interest expenses  | 30,952,924.14            | 65,761,071.64            |
| Interest income   | 274,983,078.16           | 204,414,638.64           |
| Add: Other income   | 91,453,793.37            | 106,954,396.76           |
| Investment gains (“-” indicating loss)                                | 164,837,080.44           | 1,537,653,139.20         |
| Including: Gains from investments in associates<br>and joint ventures | 138,966,489.12           | 64,002,820.43            |
| Gains from changes in fair value<br>(“-” indicating loss)             | 459,260,746.85           | -45,938,551.48           |
| Credit impairment losses (“-” indicating loss)                        | -63,930,643.66           | -78,773,317.83           |
| Assets impairment losses (“-” indicating loss)                        | -41,177,323.17           | -156,213,198.67          |
| Gains on assets disposal (“-” indicating loss)                        | 2,162,406.40             | -13,400,009.25           |
| III. Operating profit (“-” indicating loss)                           | 5,614,936,555.19         | 4,292,748,775.29         |
| Add: Non-operating income   | 6,577,970.54             | 152,777.95               |
| Less: Non-operating expenses  | 14,234,269.52            | 13,008,002.36            |
| IV. Total profit (“-” indicating total loss)                          | 5,607,280,256.21         | 4,279,893,550.88         |
| Less: Income tax expenses   | 936,766,274.88           | 564,424,709.84           |

| Item  | First quarter<br>of 2026 | First quarter<br>of 2025 |
|---|--------------------------|--------------------------|
| V. Net profit (“-” indicating net loss)   | 4,670,513,981.33         | 3,715,468,841.04         |
| (I) Classified by continuity of operations  |                          |                          |
| 1. Net profit from continuing operations<br>(“-” indicating net loss)   | 4,652,597,022.26         | 3,716,274,268.57         |
| 2. Net profit from discontinued operations<br>(“-” indicating net loss)   | 17,916,959.07            | -805,427.53              |
| (II) Classified by ownership  |                          |                          |
| 1. Net profit attributable to the owners of the<br>Company (“-” indicating net loss)                              | 4,651,517,987.76         | 3,671,960,950.47         |
| 2. Net profit attributable to non-controlling<br>shareholders (“-” indicating net loss)                           | 18,995,993.57            | 43,507,890.57            |
| VI. Other comprehensive income, net of tax  | -273,737,529.63          | 118,473,436.43           |
| (I) Other comprehensive income attributable to the<br>owners of the Company, net of tax                           | -268,621,140.23          | 120,103,150.04           |
| 1. Other comprehensive income that will not<br>be reclassified to profit or loss                                  | —                        | —                        |
| 2. Other comprehensive income that will be<br>reclassified to profit or loss                                      | -268,621,140.23          | 120,103,150.04           |
| (1) Other comprehensive income that<br>will be transferred to profit or loss<br>accounted for using equity method | —                        | —                        |
| (2) Changes in fair value of other debt<br>investments  | —                        | —                        |
| (3) Financial assets reclassified to other<br>comprehensive income  | —                        | —                        |
| (4) Credit impairment allowance of other<br>debt investments  | —                        | —                        |
| (5) Cash flow hedging reserve   | 3,057,261.88             | 126,476,899.56           |
| (6) Exchange difference on translation of<br>foreign financial statements   | -271,678,402.11          | -6,373,749.52            |
| (7) Others  | —                        | —                        |
| (II) Other comprehensive income attributable to non-<br>controlling shareholders, net of tax                      | -5,116,389.40            | -1,629,713.61            |

| Item   | First quarter<br>of 2026 | First quarter<br>of 2025 |
|--|--------------------------|--------------------------|
| VII. Total comprehensive income  | 4,396,776,451.70         | 3,833,942,277.47         |
| (I) Total comprehensive income attributable to the owners of the Company     | 4,382,896,847.53         | 3,792,064,100.51         |
| (II) Total comprehensive income attributable to non-controlling shareholders | 13,879,604.17            | 41,878,176.96            |
| VIII. Earnings per share:  |                          |                          |
| (I) Basic earnings per share (RMB per share)                                 | 1.59                     | 1.29                     |
| (II) Diluted earnings per share (RMB per share)                              | 1.58                     | 1.28                     |

For the business combination involving enterprises under common control during the Reporting Period, realized net profit of the merged parties before the merger was nil (corresponding period of the previous year: nil).

|  |          |
|--|----------|
| Person in charge of the Company:       | Ge Li    |
| Chief Financial Officer:               | Ming Shi |
| Director of the Accounting Department: | Jin Sun  |

## Consolidated Statement of Cash Flows

January to March 2026

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

| Item  | First quarter<br>of 2026 | First quarter<br>of 2025 |
|---|--------------------------|--------------------------|
| <b>I. Cash flow from operating activities:</b>  |                          |                          |
| Cash received from sale of goods or rendering of services                                     | 12,564,206,385.70        | 10,887,895,827.62        |
| Refunds of taxes and surcharges   | 529,798,491.22           | 496,033,127.37           |
| Cash received relating to other operating activities  | 466,971,301.73           | 256,410,492.70           |
| Sub-total of cash inflow from operating activities  | 13,560,976,178.65        | 11,640,339,447.69        |
| Cash paid for purchasing goods and receiving services   | 4,801,463,683.80         | 3,720,501,702.72         |
| Cash paid to and on behalf of employees   | 3,549,166,099.92         | 3,455,707,702.07         |
| Payments of taxes and surcharges  | 1,217,418,205.33         | 669,843,245.50           |
| Cash paid relating to other operating activities  | 397,117,863.07           | 598,856,935.68           |
| Sub-total of cash outflow from operating activities   | 9,965,165,852.12         | 8,444,909,585.97         |
| Net cash flow from operating activities   | 3,595,810,326.53         | 3,195,429,861.72         |
| <b>II. Cash flow from investing activities:</b>   |                          |                          |
| Cash received from disposal of investments  | 3,366,510,544.51         | 2,801,642,393.54         |
| Cash received from return on investments  | 29,116,209.77            | 20,004,957.84            |
| Net cash received from disposal of fixed assets, intangible assets and other long-term assets | 24,688,122.30            | 1,678,587.47             |
| Net cash received from disposal of subsidiaries and other business entities                   | 398,053,880.94           | 1,255,520,822.86         |
| Cash received relating to other investing activities  | —                        | —                        |
| Sub-total of cash inflow from investing activities  | 3,818,368,757.52         | 4,078,846,761.71         |
| Cash paid to acquire fixed assets, intangible assets and other long-term assets               | 1,194,798,903.26         | 734,534,627.09           |
| Cash paid to acquire investments  | 7,971,938,663.55         | 1,144,555,938.95         |
| Net cash paid to acquire subsidiaries and other business entities                             | —                        | —                        |
| Cash paid relating to other investing activities  | —                        | —                        |
| Sub-total of cash outflow from investing activities   | 9,166,737,566.81         | 1,879,090,566.04         |
| Net cash flow from investing activities   | -5,348,368,809.29        | 2,199,756,195.67         |

| Item  | First quarter<br>of 2026 | First quarter<br>of 2025 |
|---|--------------------------|--------------------------|
| <b>III. Cash flow from financing activities:</b>  |                          |                          |
| Cash received from capital contributions  | —                        | —                        |
| Including: Cash received from capital contribution by<br>non-controlling shareholders of subsidiaries | —                        | —                        |
| Cash received from borrowings   | 3,377,302,944.51         | 4,767,126,048.90         |
| Cash received relating to other financing activities  | —                        | —                        |
| Sub-total of cash inflow from financing activities  | 3,377,302,944.51         | 4,767,126,048.90         |
| Cash repayments of borrowings   | 3,400,300,000.00         | 3,408,720,026.72         |
| Cash payments for distribution of dividends, profits or<br>interest expenses                          | 16,953,610.04            | 59,416,181.89            |
| Including: Dividends and profits paid by subsidiaries to<br>non-controlling shareholders              | —                        | 15,830,160.00            |
| Cash paid relating to other financing activities  | 35,028,816.84            | 62,953,208.74            |
| Sub-total of cash outflow from financing activities   | 3,452,282,426.88         | 3,531,089,417.35         |
| Net cash flow from financing activities   | -74,979,482.37           | 1,236,036,631.55         |
| <b>IV. Effect of fluctuations in exchange rates on cash and<br/>cash equivalents</b>                  |                          |                          |
|   | -198,774,624.87          | -61,078,422.61           |
| <b>V. Net increase in cash and cash equivalents</b>   |                          |                          |
|   | -2,026,312,590.00        | 6,570,144,266.33         |
| Add: Balance of cash and cash equivalents at the<br>beginning of the period                           | 29,455,830,548.95        | 13,444,711,217.64        |
| <b>VI. Balance of cash and cash equivalents at the end of<br/>the period</b>                          |                          |                          |
|   | 27,429,517,958.95        | 20,014,855,483.97        |

|  |          |
|--|----------|
| Person in charge of the Company:       | Ge Li    |
| Chief Financial Officer:               | Ming Shi |
| Director of the Accounting Department: | Jin Sun  |

**3. Adjustments on the financial statements at the beginning of the first year of adopting new accounting standards or standard interpretations since 2026**

Applicable     Not applicable

**4. Quarterly condensed consolidated financial statements prepared in accordance with IFRS Accounting Standards**

**Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income**

January to March 2026

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

|  | Continuing Operations    |  | Discontinued Operations  |  | Total                    |                          |
|--|--------------------------|--|--------------------------|--|--------------------------|--------------------------|
|  | First quarter<br>of 2026 | First quarter<br>of 2025<br>(Restated) | First quarter<br>of 2026 | First quarter<br>of 2025<br>(Restated) | First quarter<br>of 2026 | First quarter<br>of 2025 |
| Revenue  | 12,435,777               | 8,918,594                              | —                        | 736,001                                | 12,435,777               | 9,654,595                |
| Cost of sales  | (6,237,231)              | (4,989,246)                            | —                        | (652,273)                              | (6,237,231)              | (5,641,519)              |
| <b>Gross profit</b>  | <b>6,198,546</b>         | <b>3,929,348</b>                       | <b>—</b>                 | <b>83,728</b>                          | <b>6,198,546</b>         | <b>4,013,076</b>         |
| Other income   | 357,605                  | 295,686                                | 9,225                    | 15,683                                 | 366,830                  | 311,369                  |
| Other gains and losses   | 217,750                  | 973,987                                | 13,828                   | 99,269                                 | 231,578                  | 1,073,256                |
| Impairment losses under<br>expected credit losses<br>("ECL") model, net of<br>reversal | (66,706)                 | (155,480)                              | —                        | 2,390                                  | (66,706)                 | (153,090)                |
| Impairment losses of<br>non-financial assets   | (24,479)                 | (69,474)                               | —                        | —                                      | (24,479)                 | (69,474)                 |
| Selling and marketing expenses   | (182,057)                | (164,463)                              | —                        | (29,589)                               | (182,057)                | (194,052)                |
| Administrative expenses  | (751,689)                | (497,938)                              | —                        | (99,854)                               | (751,689)                | (597,792)                |
| R&D expenses   | (266,957)                | (207,285)                              | —                        | (17,123)                               | (266,957)                | (224,408)                |
| <b>Operating profit</b>  | <b>5,482,013</b>         | <b>4,104,381</b>                       | <b>23,053</b>            | <b>54,504</b>                          | <b>5,505,066</b>         | <b>4,158,885</b>         |
| Share of results of associates   | 139,002                  | 63,936                                 | —                        | —                                      | 139,002                  | 63,936                   |
| Share of results of joint ventures   | (35)                     | 67                                     | —                        | —                                      | (35)                     | 67                       |
| Finance costs  | (36,753)                 | (73,518)                               | —                        | (6,677)                                | (36,753)                 | (80,195)                 |
| <b>Profit before tax</b>   | <b>5,584,227</b>         | <b>4,094,866</b>                       | <b>23,053</b>            | <b>47,827</b>                          | <b>5,607,280</b>         | <b>4,142,693</b>         |
| Income tax expense   | (931,630)                | (515,793)                              | (5,136)                  | (48,632)                               | (936,766)                | (564,425)                |
| <b>Profit(loss) for the period</b>   | <b>4,652,597</b>         | <b>3,579,073</b>                       | <b>17,917</b>            | <b>(805)</b>                           | <b>4,670,514</b>         | <b>3,578,268</b>         |

|   | First quarter<br>of 2026    | First quarter<br>of 2025<br>(Restated) |
|---|-----------------------------|--|
| <b>Other comprehensive (expense)income for the period</b>                                 |                             |  |
| <i>Items that may be reclassified subsequently to profit or loss:</i>                     |                             |  |
| Exchange differences arising on translation of financial statements of foreign operations | (276,740)                   | (8,896)                                |
| Fair value gain on hedging instrument designated in cash flow hedges                      | 3,002                       | 127,369                                |
|   | <u>                    </u> | <u>                    </u>            |
| <b>Other comprehensive (expense)income for the period, net of income tax</b>              | (273,738)                   | 118,473                                |
|   | <u>                    </u> | <u>                    </u>            |
| <b>Total comprehensive income for the period</b>  | <u>4,396,776</u>            | <u>3,696,741</u>                       |
| Profit(loss) for the period attributable to the owners of the Company:                    |                             |  |
| From continuing operations  | 4,633,601                   | 3,537,995                              |
| From discontinued operations  | 17,917                      | (1,730)                                |
|   | <u>                    </u> | <u>                    </u>            |
|   | <u>4,651,518</u>            | <u>3,536,265</u>                       |
| Profit for the period attributable to non-controlling interests:                          |                             |  |
| From continuing operations  | 18,996                      | 41,078                                 |
| From discontinued operations  | —                           | 925                                    |
|   | <u>                    </u> | <u>                    </u>            |
|   | <u>18,996</u>               | <u>42,003</u>                          |
| Total comprehensive income for the period attributable to:                                |                             |  |
| Owners of the Company   | 4,382,896                   | 3,656,368                              |
| Non-controlling interests   | 13,880                      | 40,373                                 |
|   | <u>                    </u> | <u>                    </u>            |
|   | <u>4,396,776</u>            | <u>3,696,741</u>                       |
| <b>Earnings per share (expressed in RMB)</b>  |                             |  |
| From continuing and discontinued operations   |                             |  |
| — Basic   | 1.59                        | 1.24                                   |
| — Diluted   | 1.58                        | 1.24                                   |
| From continuing operations  |                             |  |
| — Basic   | 1.59                        | 1.24                                   |
| — Diluted   | 1.58                        | 1.24                                   |

## Condensed Consolidated Statement of Financial Position

As at March 31, 2026

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000    Type of audit: Unaudited

|  | As at<br>March 31,<br>2026 | As at<br>December 31,<br>2025 |
|--|----------------------------|-------------------------------|
| <b>Assets</b>  |                            |                               |
| <b>Non-current Assets</b>  |                            |                               |
| Property, plant and equipment                                      | 26,561,791                 | 26,233,860                    |
| Right-of-use assets  | 1,591,110                  | 1,629,357                     |
| Goodwill   | 863,384                    | 864,389                       |
| Other intangible assets  | 393,127                    | 414,281                       |
| Interests in associates  | 2,271,966                  | 2,141,502                     |
| Interests in joint ventures  | 3,301                      | 3,375                         |
| Deferred tax assets  | 565,719                    | 531,297                       |
| Financial assets at fair value through<br>profit or loss (“FVTPL”) | 8,464,146                  | 8,131,208                     |
| Other non-current assets   | 506,470                    | 481,371                       |
| Biological assets  | 1,024,158                  | 1,013,273                     |
|  | <b>42,245,172</b>          | <b>41,443,913</b>             |
| <b>Current Assets</b>  |                            |                               |
| Inventories  | 7,820,429                  | 6,922,791                     |
| Contract costs   | 1,168,997                  | 1,101,351                     |
| Biological assets  | 976,454                    | 969,103                       |
| Amounts due from related parties                                   | 198,886                    | 147,686                       |
| Trade and other receivables  | 9,566,871                  | 9,622,588                     |
| Contract assets  | 528,213                    | 469,518                       |
| Income tax recoverable   | 8,805                      | 8,807                         |
| Financial assets at FVTPL  | 7,479,222                  | 5,806,212                     |
| Derivative financial instruments                                   | 116,808                    | 68,657                        |
| Other current assets   | 1,399,387                  | 1,402,987                     |
| Pledged bank deposits  | 23,959                     | 12,688                        |
| Term deposits with initial term of<br>over three months            | 8,451,760                  | 5,662,791                     |
| Bank balances and cash   | 27,429,518                 | 29,455,831                    |
|  | 65,169,309                 | 61,651,010                    |
| Assets classified as held for sale                                 | —                          | 26,046                        |
|  | <b>65,169,309</b>          | <b>61,677,056</b>             |
| <b>Total Current Assets</b>  | <b>65,169,309</b>          | <b>61,677,056</b>             |
| <b>Total Assets</b>  | <b>107,414,481</b>         | <b>103,120,969</b>            |

|   | As at<br>March 31,<br>2026 | As at<br>December 31,<br>2025 |
|---|----------------------------|-------------------------------|
| <b>Liabilities</b>                                  |                            |                               |
| <b>Current Liabilities</b>                          |                            |                               |
| Trade and other payables                            | 7,684,012                  | 7,833,267                     |
| Amounts due to related parties                      | 1,898                      | 20,364                        |
| Derivative financial instruments                    | 90,741                     | —                             |
| Contract liabilities                                | 2,764,251                  | 2,709,160                     |
| Bank borrowings                                     | 5,978,332                  | 5,986,738                     |
| Lease liabilities                                   | 163,501                    | 159,018                       |
| Income tax payables                                 | 2,358,750                  | 2,526,721                     |
|   | <hr/>                      | <hr/>                         |
| <b>Total Current Liabilities</b>                    | <b>19,041,485</b>          | <b>19,235,268</b>             |
|   | <hr/>                      | <hr/>                         |
| <b>Non-current Liabilities</b>                      |                            |                               |
| Bank borrowings                                     | 1,818,800                  | 1,819,100                     |
| Deferred tax liabilities                            | 444,816                    | 415,459                       |
| Deferred income                                     | 919,452                    | 948,171                       |
| Lease liabilities                                   | 418,299                    | 455,257                       |
|   | <hr/>                      | <hr/>                         |
| <b>Total Non-current Liabilities</b>                | <b>3,601,367</b>           | <b>3,637,987</b>              |
|   | <hr/>                      | <hr/>                         |
| <b>Total Liabilities</b>                            | <b>22,642,852</b>          | <b>22,873,255</b>             |
|   | <hr/> <hr/>                | <hr/> <hr/>                   |
| <b>Capital and Reserves</b>                         |                            |                               |
| Share capital                                       | 2,983,757                  | 2,983,757                     |
| Reserves  | 81,237,999                 | 76,728,533                    |
|   | <hr/>                      | <hr/>                         |
| Equity attributable to the owners of the<br>Company | 84,221,756                 | 79,712,290                    |
| Non-controlling interests                           | 549,873                    | 535,424                       |
|   | <hr/>                      | <hr/>                         |
| <b>Total Equity</b>                                 | <b>84,771,629</b>          | <b>80,247,714</b>             |
|   | <hr/>                      | <hr/>                         |
| <b>Total Equity and Liabilities</b>                 | <b>107,414,481</b>         | <b>103,120,969</b>            |
|   | <hr/> <hr/>                | <hr/> <hr/>                   |

## Condensed Consolidated Statement of Cash Flows

January to March 2026

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000    Type of audit: Unaudited

|  | <b>First quarter<br/>of 2026</b> | <b>First quarter<br/>of 2025</b> |
|--|----------------------------------|----------------------------------|
| <b>Net cash from operating activities</b>                                  | <b>3,409,800</b>                 | <b>3,029,600</b>                 |
| <b>Investing activities</b>  |                                  |                                  |
| Interests received   | 189,082                          | 143,057                          |
| Proceeds from disposal of financial assets at<br>FVTPL                     | 3,381,789                        | 1,353,762                        |
| Proceeds from partial disposal of associates<br>and a joint venture        | —                                | 1,461,407                        |
| Purchases of financial assets at FVTPL                                     | (5,103,334)                      | (1,094,037)                      |
| Purchases of term deposits with initial term of<br>over three months       | (2,866,275)                      | —                                |
| Proceeds from disposal of right-of-use assets                              | 17,400                           | —                                |
| Proceeds from disposal of property, plant and<br>equipment                 | 7,288                            | 1,679                            |
| Capital injection to an associate  | —                                | (5,601)                          |
| Purchases of property, plant and equipment                                 | (1,194,799)                      | (734,535)                        |
| Withdrawal of rental deposits  | 917                              | 809                              |
| Placement of pledged bank deposits   | (4,271)                          | (22)                             |
| Dividends received from financial assets at<br>FVTPL                       | 10,255                           | 6,478                            |
| Dividends received from an associate                                       | 3,480                            | —                                |
| Proceeds from (payments on) derivative<br>financial instruments            | 102                              | (1,644)                          |
| R&D grants and others received from various<br>countries related to assets | 1,200                            | 22,794                           |
| Payments of project fees relating to<br>discontinued operations            | (2,330)                          | (43,274)                         |
| Net cash inflow on disposal of subsidiaries                                | 398,054                          | 1,255,521                        |
| <b>Net cash (used in) from investing activities</b>                        | <b>(5,161,442)</b>               | <b>2,366,394</b>                 |

|   | <b>First quarter<br/>of 2026</b> | <b>First quarter<br/>of 2025</b> |
|---|----------------------------------|----------------------------------|
| <b>Financing activities</b>   |                                  |                                  |
| Payments of dividends   | —                                | (15,830)                         |
| New bank borrowings raised  | 3,377,303                        | 4,767,126                        |
| Repayments of bank borrowings                                       | (3,400,300)                      | (3,408,720)                      |
| Repayments of lease liabilities                                     | (35,945)                         | (63,762)                         |
| Interests paid  | (16,954)                         | (43,586)                         |
|   | <u>                    </u>      | <u>                    </u>      |
| <b>Net cash (used in)from financing activities</b>                  | <b><u>(75,896)</u></b>           | <b><u>1,235,228</u></b>          |
| <b>Net (decrease)increase in cash and cash<br/>equivalents</b>      | <b>(1,827,538)</b>               | <b>6,631,222</b>                 |
| <b>Cash and cash equivalents at the beginning<br/>of the period</b> | <b>29,455,831</b>                | <b>13,444,711</b>                |
| Effects of exchange rate changes                                    | (198,775)                        | (61,078)                         |
|   | <u>                    </u>      | <u>                    </u>      |
| <b>Cash and cash equivalents at the end of<br/>the period</b>       | <b><u>27,429,518</u></b>         | <b><u>20,014,855</u></b>         |

**5. Adjusted Non-IFRS Gross Profit, Net Profit Attributable to the Owners of the Company and Earnings Per Share**

Unit: RMB million    Type of audit: Unaudited

|   | <b>First quarter<br/>of 2026</b> | <b>First quarter<br/>of 2025</b> |
|---|----------------------------------|----------------------------------|
| <b>Net profit attributable to the owners of<br/>the Company</b>                                       | <b>4,651.5</b>                   | <b>3,536.3</b>                   |
| Add:  |                                  |                                  |
| Share-based compensation expenses   | 96.4                             | 34.4                             |
| Issuance expenses of convertible bonds  | —                                | 9.8                              |
| Foreign exchange related losses   | 250.6                            | 178.0                            |
| Amortization of acquired intangible assets<br>from merger and acquisition                             | 5.3                              | 7.1                              |
| Gains or losses from divestiture, restructuring<br>and resource integration initiatives               | (11.7)                           | 8.6                              |
|   | <u>4,992.2</u>                   | <u>3,774.1</u>                   |
| <b>Non-IFRS net profit attributable to the<br/>owners of the Company</b>                              | <b>4,992.2</b>                   | <b>3,774.1</b>                   |
| Add:  |                                  |                                  |
| Realized and unrealized gains from venture<br>capital investments                                     | (394.7)                          | (1,096.3)                        |
| Realized and unrealized share of losses (gains)<br>from joint ventures                                | 0.0                              | (0.1)                            |
|   | <u>0.0</u>                       | <u>(0.1)</u>                     |
| <b>Adjusted non-IFRS net profit attributable to<br/>the owners of the Company</b> <sup>(Note 1)</sup> | <b>4,597.5</b>                   | <b>2,677.7</b>                   |
| <b>Adjusted non-IFRS earnings per share<br/>(expressed in RMB)</b>                                    |                                  |                                  |
| — Basic   | 1.57                             | 0.94                             |
| — Diluted   | 1.57                             | 0.94                             |
| <b>Adjusted non-IFRS gross profit</b> <sup>(Note 2)</sup>   | <b>6,271.7</b>                   | <b>4,048.3</b>                   |
| <b>Adjusted non-IFRS gross profit margin:</b>   | <b>50.4%</b>                     | <b>41.9%</b>                     |
| WuXi Chemistry  | 52.8%                            | 47.5%                            |
| WuXi Testing  | 35.5%                            | 24.8%                            |
| WuXi Biology  | 36.7%                            | 36.3%                            |

*Note 1:* The discrepancies between the total and sums of amounts in the table above are due to rounding.

*Note 2:* The adjustments made to the adjusted non-IFRS gross profit mentioned above are the same as those made to the adjusted non-IFRS net profit attributable to the owners of the Company at the gross profit level.

## 6. Adjusted Free Cash Flow

Unit: RMB million    Type of audit: Unaudited

|  | First quarter of<br>2026 | First quarter of<br>2025 |
|--|--------------------------|--------------------------|
| Net cash from operating activities   | 3,409.8                  | 3,029.6                  |
| Add: Income tax expenditures related to<br>significant equity and business sales | 276.7                    | —                        |
| <b>Adjusted net cash from operating activities</b>                               | <b><u>3,686.5</u></b>    | <b><u>3,029.6</u></b>    |
| Less: Capital expenditures   | (1,194.8)                | (734.5)                  |
| <b>Adjusted free cash flow</b>   | <b><u>2,491.7</u></b>    | <b><u>2,295.1</u></b>    |

*Note:* Free cash flow refers to net cash from operating activities less capital expenditures. The adjustments to free cash flow primarily relate to income tax expenditures related to significant transactions, mainly equity or business sales, disclosed in the Company's announcements. Specifically, adjusted free cash flow for the first quarter of 2026 excludes the impact of tax payments relating to the gain arising from the divestiture of certain business, which was originally recognized in net cash from operating activities. As the gains from the divestiture of certain business constitute material non-recurring activities with related proceeds reflected in net cash from investing activities, this adjustment is necessary to ensure an accurate representation of core operating cash flows and to maintain meaningful period-to-period comparability of our financial results.